SEC Company Response from BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Aug 28, 2019

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Aug. 28, 2019 · CIK: 0001137883 · Accession: 0001144204-19-042033

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-233349

Date

August 28, 2019

Author

Chaim Lebovits

Form

CORRESP

Company

BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)

Letter

BRAINSTORM CELL THERAPEUTICS INC.

1325 Avenue of Americas 28th Floor

New York, NY 10019

August 28, 2019

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Suzanne Hayes

RE:

Brainstorm Cell Therapeutics Inc.

Registration Statement on Form S-3

Filed August 16, 2019

File No. 333-233349

Acceleration Request

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the “Company”) hereby respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday, August 30, 2019, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.

Any questions regarding this request should be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.

Very truly yours,
Brainstorm Cell Therapeutics Inc.

Show Raw Text

CORRESP
1
filename1.htm

BRAINSTORM CELL THERAPEUTICS INC.

1325 Avenue of Americas 28th Floor

New York, NY 10019

    August 28, 2019

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C.  20549

Attention: Suzanne Hayes

    RE:

        Brainstorm Cell Therapeutics Inc.

        Registration Statement on Form S-3

        Filed August 16, 2019

        File No. 333-233349

        Acceleration Request

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations
promulgated under the Securities Act of 1933, as amended, Brainstorm Cell Therapeutics Inc. (the “Company”) hereby
respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 be accelerated to Friday,
August 30, 2019, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter.

Any questions regarding this request should
be addressed to Thomas B. Rosedale, Esq., at BRL Law Group LLC at (617) 399-6931.

        Very truly yours,

        Brainstorm Cell Therapeutics Inc.

            /s/ Chaim Lebovits

        By: Chaim Lebovits

        Its:  President and Chief Executive Officer

 cc: Thomas B. Rosedale, Esq.

(BRL Law Group LLC)

SecProbe.io